Breaking News
November 19, 2017 - Researchers identify possible genetic basis for coronary artery disease
November 19, 2017 - Stress experienced by emergency call handlers has negative impact on psychological health
November 18, 2017 - New cancer cell screening is improving childhood leukaemia treatment
November 18, 2017 - Groundbreaking study identifies protein as potential factor in cancer metastasis
November 18, 2017 - New model to test effectiveness of existing and potential CF therapies
November 18, 2017 - Staying Active May Lower Odds for Glaucoma
November 18, 2017 - Potential new autism drug shows promise in mice
November 18, 2017 - Some states roll back ‘retroactive Medicaid,’ a buffer for the poor — and for hospitals
November 18, 2017 - Selectively deleting stem cell factor promotes recovery after TBI in mice
November 18, 2017 - Breakthrough research brings new procedure closer to helping patients with blood cancer
November 18, 2017 - Dr Peter Simpson Appointed to SLAS Board of Directors
November 18, 2017 - Friendships between young children can protect against ADHD
November 18, 2017 - Old World monkeys could hold key to stop progression of rheumatoid arthritis
November 18, 2017 - Harris Health System RNs named among 20 Outstanding Nurses for 2017
November 18, 2017 - Old World monkeys could be key to a new, powerful rheumatoid arthritis therapy
November 18, 2017 - Mount Sinai researchers identify new therapeutic target for ER+ breast cancer
November 18, 2017 - Age, CRP levels predict success in tapering of biologics in rheumatoid arthritis patients
November 18, 2017 - New dye could be used to observe electrical activity of neurons in the brain
November 18, 2017 - New study further validates use of vaginal progesterone to decrease risk of preterm birth
November 18, 2017 - Russian researcher determined range of reference values for boron in the human body
November 18, 2017 - ‘What the Health?’ Tax bill or health bill?
November 18, 2017 - Could Your Cat Give You ‘Bird Flu?’
November 18, 2017 - Vitamin D Linked to Fertility Outcomes in ART
November 18, 2017 - Neuroscientists identify genetic changes in microglia in a mouse model of neurodegeneration and Alzheimer’s disease
November 18, 2017 - Tax reform proposal could impact care for older Americans
November 18, 2017 - PCSK9 inhibitor offers clinical benefit to patients with peripheral artery disease
November 18, 2017 - Researchers receive £1.3 million to develop sight-saving imaging technology
November 18, 2017 - Novel buckypaper sensor could pave way for high-performance, affordable wearable technology
November 18, 2017 - Despite ACA cost protections, most adolescents skip regular checkups
November 18, 2017 - Stem cell treatment allows paraplegic rats to walk and regain sensory perception
November 18, 2017 - HTC analytical conference comes to the UK
November 18, 2017 - Face It: Drinking, Smoking Takes Toll on Looks: MedlinePlus Health News
November 18, 2017 - New research shows where in the brain the earliest signs of Alzheimer’s occur
November 18, 2017 - Philips announces launch of global movement to raise awareness for COPD
November 18, 2017 - University of Bristol awarded grant to reduce antibacterial drug resistance in Thailand
November 18, 2017 - New oxytocin chemical sensor could be first step towards early diagnosis of autism
November 18, 2017 - Study shows how naïve T-cells may affect tumor immunity and immunotherapy
November 18, 2017 - New studies highlight importance of cardiorespiratory fitness to reduce CVD risk
November 18, 2017 - Study finds medical cannabis is effective at reducing opioid addiction
November 18, 2017 - Specially tailored, ultrafast light pulses can trigger neurons to fire in different patterns
November 18, 2017 - Decrease in sunshine linked to rising incidence of Rickets
November 18, 2017 - Harnessing social media big data to fight against prescription drug crisis
November 18, 2017 - Researchers find way to switch tumor cells between 2D and 3D morphology
November 18, 2017 - FDA Approves Hemlibra (emicizumab-kxwh) for Hemophilia A with Inhibitors
November 18, 2017 - Adolescents underreport amphetamine use, likely unaware that adderall is amphetamine
November 18, 2017 - Study reveals a reduced risk of teenage eczema in breastfed babies
November 18, 2017 - Separating side effects could pave way for safe, effective pain medications
November 18, 2017 - Gut bacteria at young age can contribute to MS disease onset and progression, study suggests
November 18, 2017 - Environmental triggers may play role in development of Lupus
November 18, 2017 - Review looks into conventional versus new treatment modalities in orthodontic pain management
November 17, 2017 - FDA Alert: Diphenoxylate Hydrochloride and Atropine Sulfate Tablets by Greenstone: Recall
November 17, 2017 - For older women, every movement matters
November 17, 2017 - Talking-based therapy could transform aftercare for cancer survivors
November 17, 2017 - Olympus IXplore SpinSR10 imaging system enables researchers to observe fine details in live cells
November 17, 2017 - Study explores reasons for underrepresentation of minorities in genetic cancer research
November 17, 2017 - California firm running physician practices is closing down as scrutiny ramps up
November 17, 2017 - BMI not valid measure of obesity in postmenopausal women, study shows
November 17, 2017 - Vaginal progesterone decreases the risk of premature birth in women with short cervix
November 17, 2017 - Pricey ER Tests for Chest Pain Often Unnecessary
November 17, 2017 - ‘Old’ Lungs May Be Good Transplant Options: MedlinePlus Health News
November 17, 2017 - How not to gain weight over the holidays
November 17, 2017 - Researchers map first-ever proteome of healthy human heart
November 17, 2017 - Drug used to prevent and treat malaria may also be effective for Zika virus
November 17, 2017 - One in 20 children still receiving codeine to treat pain despite warning from federal regulators
November 17, 2017 - Improving clinical trials with machine learning
November 17, 2017 - Experts identify mental exercise program that can reduce risk of dementia
November 17, 2017 - Just-in-time 3-D implants set to transform tumor surgery
November 17, 2017 - Skin patch offers hope for people with peanut allergy
November 17, 2017 - Scientists identify biomarkers that predict risk of death in Ebola patients
November 17, 2017 - Heart attack, stroke patients have improved outcomes when statins are prescribed after discharge
November 17, 2017 - Majority of people do not understand link between obesity and cancer, study shows
November 17, 2017 - Deep vein thrombosis accurately diagnosed by GPs trained in compression ultrasonography
November 17, 2017 - New Kevlar-based hydrogel recreates the magic of natural cartilage
November 17, 2017 - FDA approves first adjuvant treatment to reduce risk of kidney cancer recurrence
November 17, 2017 - Foods made with biofortified corn flour and eggs retain vitamin A after cooking
November 17, 2017 - Integrated Care Winning the Day for Healthcare Companies
November 17, 2017 - CPAP may be superior to gastric banding for severe sleep apnea
November 17, 2017 - New pain relievers reduce opiate overdose risk
November 17, 2017 - Brain astrocytes could play key role in pathogenesis of Alzheimer’s disease
November 17, 2017 - Researchers test whether LVAD surgery could reverse frailty in older adults with heart failure
Including Drug to Same old Care Would possibly Extend Lymphoma Survival

Including Drug to Same old Care Would possibly Extend Lymphoma Survival

image_pdfDownload PDFimage_print

HealthDay news image

WEDNESDAY, Sept. 27, 2017 (HealthDay Information) — Lengthy-term remedy with the drug rituximab (Rituxan) might lengthen the lives of a few sufferers with an extraordinary type of blood most cancers, a brand new medical trial unearths.

The illness, referred to as mantle-cell lymphoma, is usually incurable. However quite a lot of therapies can extend other people’s lives. Some sufferers, as an example, are in a position to go through chemotherapy to wipe out the most cancers cells, adopted by way of a stem cellular transplant — to revive customary blood cells.

However whilst that means will also be efficient for some time, maximum sufferers see the most cancers come again.

So the brand new trial, funded by way of Rituxan maker Roche, checked out whether or not an extra step may assist: Having sufferers take Rituxan for 3 years following their stem cellular transplant.

Total, researchers discovered, the strategy did enhance sufferers’ outlook. After 4 years, 83 p.c of rituximab sufferers had been nonetheless alive and progression-free — as opposed to 64 p.c of sufferers who had same old remedy on my own.

Professionals mentioned the findings must have a direct have an effect on on sufferers’ remedy.

“This must be regarded as a brand new same old of care,” mentioned Dr. Anas Younes, leader of the lymphoma carrier at Memorial Sloan Kettering Most cancers Middle, in New York Town.

Alternatively, there are considerations with the long-term use of rituximab, consistent with Younes, who wasn’t concerned within the learn about.

The drug suppresses the immune device, so infections are at all times a possibility, he famous.

“However,” Younes added, “the advantages appear to outweigh the dangers.”

Dr. Steven Le Gouill, of Nantes Scientific College, in France, led the learn about.

He agreed that “rituximab repairs” — the usage of it long-term, after a stem cellular transplant — must turn into a brand new same old.

“The achieve in the case of total survival must inspire hematologists to prescribe rituximab repairs for transplanted sufferers,” Le Gouill mentioned.

Mantle-cell lymphoma is one in every of about 70 subtypes of non-Hodgkin lymphoma, consistent with the Leukemia & Lymphoma Society. In the USA, about four,200 individuals are identified with the illness every 12 months — maximum regularly, older males.

Medical doctors have lengthy used rituximab to regard sure cancers, together with mantle-cell lymphoma. The drug is a lab-engineered antibody that latches onto a protein on white blood cells (lymphocytes) known as B cells; the ones are the cells which are affected in mantle-cell lymphoma.

Because it stands, rituximab is used in conjunction with high-dose chemotherapy medicine to wipe out the cancerous B cells. Some sufferers then go through an “autologous” stem cellular transplant. That implies they’ve a few of their very own blood-forming stem cells got rid of prior to their drug routine; in a while, the stem cells are infused again into the frame, to revive new, wholesome blood cells.

Some sufferers — together with those that are older and frail — can not have a transplant.

However different analysis has proven that rituximab repairs, given after same old drug remedy to power out the most cancers, can lengthen the ones sufferers’ lives, Younes mentioned.

The brand new findings display the similar is correct for sufferers who do have a transplant.

The trial concerned 299 sufferers who had been more youthful than 66 once they had been identified with mantle-cell lymphoma. All underwent same old drug remedy, with rituximab and chemotherapy. Maximum — 86 p.c — spoke back neatly sufficient to go through a stem cellular transplant.

Part of the sufferers had been then randomly assigned to a few years of rituximab repairs remedy, receiving IV infusions of the drug each two months. The remaining had been adopted up with same old care.

After 4 years, 89 p.c of rituximab sufferers had been nonetheless alive, in comparison with 80 p.c within the comparability staff, the investigators discovered.

The rituximab sufferers had been additionally much more likely to stay freed from a most cancers relapse, or severe negative effects — together with critical infections and allergies: That was once true of 79 p.c of rituximab sufferers, as opposed to 61 p.c of sufferers on same old care.

In line with Le Gouill, “Rituximab repairs after stem cellular transplant is one new weapon within the arsenal to struggle towards mantle-cell lymphoma.”

He famous that different therapies were lately authorized — oral medicine that focus on abnormalities at the most cancers cells — whilst nonetheless others are in construction.

Like different antibody medicine, rituximab is pricey — operating 1000’s of greenbacks per thirty days after medical institution fees, consistent with a printed record. Repayment “might be a topic in some nations,” Le Gouill famous.

However, he added, the associated fee needs to be weighed towards the truth that the drug lengthens sufferers’ lives and has “low toxicity.”

Younes mentioned that the “vital message” from the findings is that sufferers’ survival time is constant to enhance.

The learn about findings had been printed Sept. 28 within the New England Magazine of Medication.

SOURCES: Steven Le Gouill, M.D., Ph.D., hematology carrier, Nantes Scientific College, Nantes, France; Anas Younes, M.D., leader, lymphoma carrier, Memorial Sloan Kettering Most cancers Middle, New York Town; Sept. 28, 2017, New England Magazine of Medication

Information tales are written and equipped by way of HealthDay and don’t replicate federal coverage, the perspectives of MedlinePlus, the Nationwide Library of Medication, the Nationwide Institutes of Well being, or the U.S. Division of Well being and Human Products and services.

Tagged with:

About author

Related Articles